Event Free Survival at 12 Months and 24 Months as Predictors for Outcome of Systemic Peripheral T Cell Lymphoma: Analysis of Nationwide Thai Lymphoma Study Group

Hematological Oncology - United Kingdom
doi 10.1002/hon.88_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Progression Free Survival at 12 Months After First-Line Therapy Is Associated With Favourable Outcomes After First Relapse/Progression in Peripheral T-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Predictors of Developmental Outcome at 12 Months of <1250 Gram Inborn Neonates

Pediatric Research
Child HealthPediatricsPerinatology
1984English

Cognitive Impairment After 6 and 12 Months of Hodgkin Lymphoma Treatment

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Angioimmunoblastic T-Cell Lymphoma: A Rare Subtype of Peripheral T-Cell Lymphoma

Clinical Case Reports
Medicine
2018English

Figure 2: Nomogram for Predicting 6 Months, 12 Months, 18 Months and 24 Months Cancer-Specific Death of VEOPC Patients.

English

Peripheral T-Cell Lymphoma Mimicking Marginal Zone B-Cell Lymphoma

Modern Pathology
Forensic MedicinePathology
2002English

Hematopoietic SCT for Peripheral T-Cell Lymphoma

Bone Marrow Transplantation
TransplantationHematology
2008English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Crescentic Glomerulonephritis Developing 3 Months After Autologous Peripheral Blood Stem Cell Transplantation for Non-Hodgkin’s Lymphoma

Bone Marrow Transplantation
TransplantationHematology
1998English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy